{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-24-000027","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.278664+00:00","generated_at":"2026-06-07T02:24:32.166858+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Scholar Rock provides 2024 pipeline update; Phase 3 SMA trial topline data expected Q4 2024","bullets":["Cash and equivalents of ~$280M as of Dec 31, 2023; projected to fund operations into H2 2025.","Enrollment completed for apitegromab pivotal Phase 3 SAPPHIRE in SMA; topline data expected Q4 2024.","Phase 2 proof-of-concept trial of apitegromab with GLP-1 RA in obesity to start mid-2024.","SRK-439 IND for obesity planned in 2025; preclinical data at Keystone Symposia in Feb 2024.","Presenting at J.P. Morgan Healthcare Conference on Jan 9, 2024 at 1:30 p.m. PT."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-24-000027","json":"https://secwatch.observer/filing/0001157523-24-000027.json","markdown":"https://secwatch.observer/filing/0001157523-24-000027.md","text":"https://secwatch.observer/filing/0001157523-24-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000115752324000027/0001157523-24-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000115752324000027/a53878319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:24:32.166858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}